TY - JOUR
T1 - Consensus statements on ablative radiotherapy for oligometastatic prostate cancer
T2 - A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)
AU - D'Angelillo, Rolando M
AU - Francolini, Giulio
AU - Ingrosso, Gianluca
AU - Ravo, Vincenzo
AU - Triggiani, Luca
AU - Magli, Alessandro
AU - Mazzeo, Ercole
AU - Arcangeli, Stefano
AU - Alongi, Filippo
AU - Jereczek-Fossa, Barbara A
AU - Pergolizzi, Stefano
AU - Pappagallo, Giovanni L
AU - Magrini, Stefano M
N1 - Copyright © 2019 Elsevier B.V. All rights reserved.
PY - 2019/6
Y1 - 2019/6
N2 - Oligometastatic prostate cancer comprises a wide spectrum of conditions, ranging from de novo oligometastatic cancer at diagnosis to oligometastatic castration-resistant disease, which are distinct entities in terms of biology and prognosis. In order to clarify and standardize the clinical role of ablative radiotherapy in oligometastatic prostate cancer, the Italian Association of Radiotherapy and Clinical Oncology (AIRO) formed an expert panel to review the current literature and develop a formal consensus. Oligometastatic prostate cancer was defined as the presence of up to three metastatic lesions involving bones or nodes outside pelvis. Thereafter, four clinical scenarios were explored: metastatic castration-sensitive disease at diagnosis and after primary treatment, and metastatic castration-resistant disease at diagnosis and during treatment, where the role of ablative radiotherapy was defined either in conjunction with systemic therapy or as the only treatment in selected cases. This paper summarizes the current literature about these issues and the proposed recommendations.
AB - Oligometastatic prostate cancer comprises a wide spectrum of conditions, ranging from de novo oligometastatic cancer at diagnosis to oligometastatic castration-resistant disease, which are distinct entities in terms of biology and prognosis. In order to clarify and standardize the clinical role of ablative radiotherapy in oligometastatic prostate cancer, the Italian Association of Radiotherapy and Clinical Oncology (AIRO) formed an expert panel to review the current literature and develop a formal consensus. Oligometastatic prostate cancer was defined as the presence of up to three metastatic lesions involving bones or nodes outside pelvis. Thereafter, four clinical scenarios were explored: metastatic castration-sensitive disease at diagnosis and after primary treatment, and metastatic castration-resistant disease at diagnosis and during treatment, where the role of ablative radiotherapy was defined either in conjunction with systemic therapy or as the only treatment in selected cases. This paper summarizes the current literature about these issues and the proposed recommendations.
KW - Consensus
KW - Humans
KW - Male
KW - Neoplasm Metastasis/pathology
KW - Prognosis
KW - Prostatic Neoplasms/pathology
KW - Radiosurgery/methods
KW - Radiotherapy/methods
U2 - 10.1016/j.critrevonc.2019.03.014
DO - 10.1016/j.critrevonc.2019.03.014
M3 - Review article
C2 - 31092381
VL - 138
SP - 24
EP - 28
JO - Crit. Rev. Oncol. Hematol.
JF - Crit. Rev. Oncol. Hematol.
SN - 1879-0461
ER -